Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213657 | 0.97 | PTPN1 (0.45) | PTPN1PTPN2SLC6A2SLC6A3 | |
| SCHEMBL3223792 | 0.95 | PTPN1 (0.48) | PTPN1PTPN2OPRD1PPARDPPARA | |
| SCHEMBL4557127 | 0.91 | PTPN1 (0.45) | PTPN1PTPN2OPRD1PPARDPPARA | |
| SCHEMBL2936255 | 0.88 | PTPN1 (0.47) | PTPN1PTPN2 | |
| SCHEMBL2939018 | 0.85 | SLC6A2 (0.34) | PTPN1SLC6A2SLC6A3OPRD1PPARD | |
| SCHEMBL2937456 | 0.84 | PTPN1 (0.48) | PTPN1PTPN2 | |
| SCHEMBL3201374 | 0.81 | PTPN1 (0.48) | PTPN1PTPN2PPARDPPARAPPARG | |
| SCHEMBL3926366 | 0.81 | PTPN1 (0.41) | PTPN1PTPN2PPARDPPARAPPARG | |
| Potassium SCHEMBL3930878 | 0.81 | PTPN1 (0.41) | PTPN1PTPN2PPARDPPARAPPARG | |
| SCHEMBL2937678 | 0.81 | PTPN1 (0.47) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227245-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068689-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |